"Last year, health IT had a record investment from venture capital firms--$4.1 billion--and the numbers are growing tremendously," Brailer (Read more...)
It wasn’t long ago that the antibiotics landscape was barren of startups with fresh ideas. But government initiatives like the Generating Antibiotics Initiatives Now (GAIN) Act—and, of course, (Read more...)
Gregory Verdine left a tenured position at Harvard University last year to lead a Cambridge, MA, startup trying to derive new drugs from the microbes in plants and (Read more...)
At a North Carolina conference full of life science professionals, technology companies made the loudest investment noise.
Investments in tech companies last year outpaced life science dealflow, both (Read more...)
We’re just over a week away from bringing the Big Apple biotech community together for a taste of what it takes to make it here—and what big stories (Read more...)
There have been many attempts over the years to bring together large amounts of biological and drug activity data, winnow them computationally, and come up with insights that would not (Read more...)
Here's a review on a topic that I'll bet not too many medicinal chemists have thought about in detail: noncovalent interactions with sulfur atoms. Sulfur's a weird element - small (Read more...)
Much has been made of the push to better engage patients, but little has been spent on examining exactly what patients want. Despite the requirements set by the EHR Incentive (Read more...)
The SEC is specifically warning drug companies to be more forthcoming about their dealings with the FDA. He's definitely got a point. Too many companies try to act as if (Read more...)
This blog was written by Tom Hughes, CEO of Zafgen, as part of the “From the Trenches” feature of LifeSciVC.
Last week on February 28th – as I (Read more...)
First of all, it’s not really an anti-aging startup. That’s one takeaway after sitting down with the founders of Elysium Health last week.
The newly launched company (Read more...)